Logo Image
|Videos|July 6, 2022

Dr. Garmezy on impact of antibody-drug conjugates on bladder cancer treatment paradigm

“What’s really exciting over the next few years is how are these antibody-drug conjugates that are already FDA-approved going to partner with other current drugs that we can use to treat this disease, such as immunotherapy,” says Garmezy.

Benjamin Garmezy, MD, discusses the FDA-approved antibody-drug conjugates (ADCs) enfortumab vedotin (Padcev) and sacituzumab govitecan (Trodelvy) and the next steps with ADCs in the treatment paradigm for patients with urothelial carcinoma.

Garmezy is assistant director of Genitourinary Research at Sarah Cannon Research Institute at Tennessee Oncology.

Related Content

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies
Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

View more
Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis
Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

View more